(Q56454451)

1

0 references

Raffit Hassan

2

0 references

David J. FitzGerald

3

0 references

Robert J. Kreitman

https://scigraph.springernature.com/pub.10.1038/nrc1891

4

0 references

language of work or name

English

0 references

publication date

July 2006

0 references

published in

Nature Reviews Cancer

0 references

volume

6

0 references

issue

7

0 references

page(s)

559-565

0 references

exact match

0 references

cites work

Recombinant immunotoxins for treating cancer

1 reference

Immunotoxin therapy of hematologic malignancies

21 January 2018

1 reference

Immunotoxins for treatment of leukemia and lymphoma

21 January 2018

1 reference

Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor.

21 January 2018

1 reference

Behavior of diphtheria toxin T domain containing substitutions that block normal membrane insertion at Pro345 and Leu307: control of deep membrane insertion and coupling between deep insertion of hydrophobic subdomains

21 January 2018

1 reference

Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer

21 January 2018

1 reference

The IL-2/IL-2 receptor system: a current overview

21 January 2018

1 reference

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

21 January 2018

1 reference

A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

21 January 2018

1 reference

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

21 January 2018

1 reference

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials

21 January 2018

1 reference

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity

21 January 2018

1 reference

Improving antibody affinity by mimicking somatic hypermutation in vitro

21 January 2018

1 reference

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.

21 January 2018

1 reference

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

Monoclonal antibodies for brain tumour treatment

21 January 2018

1 reference

Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study

21 January 2018

1 reference

Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma

21 January 2018

1 reference

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome

21 January 2018

1 reference

Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity

21 January 2018

1 reference

Pegylation: engineering improved pharmaceuticals for enhanced therapy

21 January 2018

1 reference

A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin

21 January 2018

1 reference

BR96 sFv-PE40 immunotoxin: nonclinical safety assessment

21 January 2018

1 reference

Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice

21 January 2018

1 reference

Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies

31 March 2020

1 reference

Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)

31 March 2020

1 reference

Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma

31 March 2020

1 reference

Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2

31 March 2020

1 reference

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

31 March 2020

1 reference

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma

31 March 2020

1 reference

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

31 March 2020

1 reference

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

31 March 2020

1 reference

Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey

31 March 2020

1 reference

Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin

31 March 2020

1 reference

Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor

31 March 2020

1 reference

The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage

31 March 2020

1 reference

Influence of immunogenicity on the pharmacokinetics of BMS-191352, a Pseudomonas exotoxin immunoconjugate, in rats and dogs

31 March 2020

1 reference

Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies

31 March 2020

1 reference

The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunotherapy of Hodgkin's lymphoma

1 reference